Shijiazhuang Dingmin pharmaceutical Sciences Co.,Ltd
sales@dingminpharma.com
86-311-67260775
Modell: CAS 1421373-65-0
Marke: DM
Grade Standard: Medicine Grade
Type: Chemical Reagent
State: Solid
Volatile: Not Volatile
Verpakung: Doppelpe mit Aluminiumfolienbeutel
Produktivität: 100kg/month
Transport: Ocean,Air
Ort Von Zukunft: Hebei, China
Unterstützung über: 100kg/month
Zertifikate : ISO9001
Hafen: Shanghai
Zahlungsart: L/C,T/T,Paypal
Incoterm: FOB,CIF
| Item Name | AZD-9291/ Osimertinib |
| CAS NO | 1421373-65-0 |
| Function |
Osimertinib (previously known as mereletinib or AZD9291) is a third-generation epidermal growth factor receptor tyrosine kinase inhibitor drug.
Osimertinib is a Kinase Inhibitor. The mechanism of action of osimertinib is as a Kinase Inhibitor, and Cytochrome P450 3A Inhibitor, and Cytochrome P450 3A4 Inducer, and Cytochrome P450 1A2 Inducer, and Breast Cancer Resistance Protein Inhibitor.
Osimertinib used in the therapy of selected forms of advanced non-small cell lung cancer (NSCLC). Osimertinib is associated with a moderate rate of serum aminotransferase elevations during therapy and rare instances of clinically apparent acute liver injury. |
| Apparence | White Powder |
| Package | Aluminum Bag;Drums;Paper Box Outside |
| Shipment | FedEx;DHL;UPS;TNT;EMS;Sea;Air. |
| Payment | Western Union;T/T;Trade Assurance;L/C |
| Warranty | 2 Years |
Wir sind der professionelle Hersteller von API, Rohstoff Pharma, pharmazeutische Zwischenprodukte, aktive pharmazeutische Inhaltsstoffe, agrochemische Zwischenprodukte und Feinschemikalien.
Produktgruppe : APIs und Zwischenprodukte > Apispulver
Privacy statement: Your privacy is very important to Us. Our company promises not to disclose your personal information to any external company with out your explicit permission.
Fill in more information so that we can get in touch with you faster
Privacy statement: Your privacy is very important to Us. Our company promises not to disclose your personal information to any external company with out your explicit permission.
Contact Now